News Analysis

The Latest

If Nobody Slashes the Price of Truvada for PrEP, What Happens Next?

Activists and doctors say they're ready to go further if Gilead won't agree to -- or the U.S. government won't force -- a price reduction to make PrEP accessible to more Americans who need it.

By Tim Murphy

How Activists Uncovered CDC's Ownership of Truvada PrEP Patents

The #PrEP4All campaign made the call for affordable pre-exposure prophylaxis a national news story.

By Charles Sanchez

Dovato Is a Newly Approved Two-Drug HIV Regimen. Do Fewer Drugs Mean a Lower-Cost HIV Treatment?

Advocates say the price is a step in the right direction. But does it go far enough?

By Tim Murphy

Sticker Shock: PrEP Is Not Cost-Effective at Current Price, Health Economists Find

But a survey reveals that about a third of black and Latino gay men would be willing to pay more than $50 per month for a prescription.

By Sony Salzman

PrEP Pricing Is the Elephant in the Room at the CDC National HIV Prevention Conference

In a debate during a plenary session, Michael Saag, M.D., argued for more activism to make PrEP accessible to people who need it.

By Sony Salzman

The Trump Administration's Drug Pricing Proposals for People With HIV, Explained

Drug pricing expert Tim Horn helps us make sense of the administration's future plans for the Medicare Part D and 340B programs.

By Tim Murphy

In the Battle to Control Drug Costs, Old Patent Laws Get New Life

Patients' rights activists and health industry's big players are usually at odds with each other, but now they are championing similar tactics to tame prescription drug prices.

By Shefali Luthra for Henry J. Kaiser Family Foundation

In the Senate, the 340B Drug Pricing Program Finds More Backers Than Detractors

Despite the tremendous success of the program -- or perhaps because of it -- and courtesy of a substantial lobbying push from the Pharmaceutical Research and Manufacturers of America (PhRMA), the 340B program has found itself under close scrutiny by ...

By AIDS United

Drug Pricing Program That Supports AIDS Service Organizations Is Under Attack

A federal drug pricing program that most Americans have never heard of has caused an all-out scrum between the big pharmaceutical and hospital lobbies, with Ryan White clinics and community health centers caught in the tussle.

By Drew Gibson

Administration Attacks on Drug Pricing Program Have Advocates Worried

A program that lowers drug costs for Ryan White clinics, community health centers, family planning clinics, and hospitals serving low-income patients is under attack by Republicans in Congress and the Trump Administration.

By Richard Sorian for AIDS United